SYRS
Syros Pharmaceuticals, Inc. Common Stock
SYRS
SYRS
Delisted
SYRS was delisted on the 19th of March, 2025.
93 hedge funds and large institutions have $405M invested in Syros Pharmaceuticals, Inc. Common Stock in 2020 Q3 according to their latest regulatory filings, with 22 funds opening new positions, 21 increasing their positions, 37 reducing their positions, and 8 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
more funds holding in top 10
Funds holding in top 10: →
less capital invested
Capital invested by funds: $ → $
43% less repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 37
54% less call options, than puts
Call options by funds: $11K | Put options by funds: $24K
Holders
93
Holding in Top 10
3
Calls
$11K
Puts
$24K
Top Buyers
| 1 | +$23.9M | |
| 2 | +$7.55M | |
| 3 | +$1.49M | |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.17M |
| 5 |
HIM
Hillsdale Investment Management
Toronto,
Ontario, Canada
|
+$683K |
Top Sellers
| 1 | -$7.74M | |
| 2 | -$4.79M | |
| 3 | -$4.61M | |
| 4 |
AVM
Arch Venture Management
Chicago,
Illinois
|
-$1.77M |
| 5 |
SB
Samsara BioCapital
Palo Alto,
California
|
-$1.35M |